NCT04977167 2024-10-10
Clinical Trial of HG146 Administered to Subjects with Advanced Solid Tumors or Lymphoma
HitGen Inc.
Phase 1 Unknown
Clinical Trials
1,136 trialsNCT05452668 2024-08-21
Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia Patients
Children's Cancer Hospital Egypt 57357
Phase NA Unknown
NCT06149169 2024-08-21
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2 Unknown
NCT06512272 2024-07-22
VOIR
Anglia Ruskin University
Phase NA Unknown
NCT03275493 2024-05-28
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1/2 Unknown
NCT06078306 2024-04-22
CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT05606380 2024-04-16
A Phase I Study to Investigate the Safety, Tolerability and PK of HLX60 (Anti-GARP Monoclonal Antibody) in Subjects With Solid Tumors or Lymphoma
Shanghai Henlius Biotech
Phase 1 Unknown
NCT02232516 2024-04-10
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT03213977 2024-03-27
R-DA-EDOCH Versus R-CEOP90, With/Without Upfront Auto-HSCT in Young Patients With High-risk DLBCL
Fujian Medical University
Phase 3 Unknown
NCT05995873 2024-03-26
A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.
MindLight, LLC
Phase NA Unknown
NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT06033820 2024-03-13
Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL
RenJi Hospital
Phase 2 Unknown
NCT02242097 2024-03-12
Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma
Northwestern University
Phase 2 Unknown
NCT05838599 2024-03-12
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Northwestern University
Phase EARLY_PHASE1 Unknown
NCT03580109 2024-03-06
THERMOEDEME
Association Francaise pour la Recherche Thermale
Phase NA Unknown
NCT04601584 2024-03-06
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
Phase 1/2 Unknown
NCT05370547 2024-03-06
Chidamide Bridging for CAR-T Therapy
Chinese PLA General Hospital
Phase 1/2 Unknown
NCT06293586 2024-03-05
Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery
Cairo University
Phase NA Unknown
NCT06290817 2024-03-04
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT03576378 2024-02-26
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 1/2 Unknown
NCT06277011 2024-02-26
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research
Anhui Provincial Hospital
Phase EARLY_PHASE1 Unknown
NCT06206902 2024-02-23
F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Unknown
NCT03650933 2024-02-20
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Nanjing Yoko Biomedical Co., Ltd.
Phase 3 Unknown
NCT06148220 2024-02-16
A Study of the Clinical Application of [18F]RCCB6 and [68Ga]Ga-NOTA-RCCB6 PET/CT Imaging in the Diagnosis of CD70-expressing Multiple Tumors
Huashan Hospital
Phase NA Unknown
NCT05284825 2024-02-15
A Phase II Trial of Intermediate Radiation Dose For Lymphoma
Sunnybrook Health Sciences Centre
Phase NA Unknown
NCT05904522 2024-02-13
Histopathological Changes in Mycosis Fungoides
Bezmialem Vakif University
Phase NA Unknown
NCT05875428 2024-02-08
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT04582487 2024-02-07
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase NA Unknown
NCT04731974 2024-02-07
Acute Concussion and Melatonin
Children's National Research Institute
Phase 2 Unknown
NCT05234684 2024-02-07
BELIEVE-01
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Unknown
NCT05358379 2024-02-07
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT04137900 2024-02-05
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Phase 1 Unknown
NCT03789097 2024-01-30
Vaccination With Flt3L, Radiation, and Poly-ICLC
Icahn School of Medicine at Mount Sinai
Phase 1/2 Unknown
NCT05422521 2024-01-30
CART-Omic
Centre Hospitalier Universitaire de Nice
Phase NA Unknown
NCT04983810 2024-01-25
A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma
Cyclacel Pharmaceuticals, Inc.
Phase 1/2 Unknown
NCT05150405 2024-01-23
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
Qilu Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT05186012 2024-01-23
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
Ascentage Pharma Group Inc.
Phase 1/2 Unknown
NCT05450146 2024-01-23
Trial-based Effectiveness and Cost-effectiveness of the Partner in Balance Intervention
Maastricht University
Phase NA Unknown
NCT06211881 2024-01-18
Chi-GVM Regimen for the Treatment of R/R PTCL
The First Affiliated Hospital with Nanjing Medical University
Phase NA Unknown
NCT06209671 2024-01-17
INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1 Unknown
NCT06201507 2024-01-12
BV-AVD-R Treatment Children Hodgkin's Lymphoma
Beijing Children's Hospital
Phase 2 Unknown
NCT05590221 2024-01-08
Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT05420493 2024-01-05
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1 Unknown
NCT04090268 2024-01-02
SportTherapy
University of Milano Bicocca
Phase NA Unknown
NCT04715217 2023-12-29
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 1/2 Unknown
NCT05460767 2023-12-29
Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Unknown
NCT05757466 2023-12-19
Prolgo-HL
St. Petersburg State Pavlov Medical University
Phase 2 Unknown
NCT01827605 2023-12-14
A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Fondazione Italiana Linfomi - ETS
Phase 3 Unknown
NCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown